South & Central America Anti-Obesity Drugs Market Report 2031 by Segments, Geography, Dynamics, Recent Developments, and Strategic Insights

The South & Central America Anti-Obesity Drugs Market size is expected to reach US$ 1,094.6 Million by 2031 from US$ 248.9 Million in 2024. The market is estimated to record a CAGR of 25.4% from 2025 to 2031.

Executive Summary and South & Central America Anti-Obesity Drugs Market Analysis:

The anti-obesity drugs market in South & Central America is segmented into Brazil, Argentina, and the Rest of South & Central America. The market in South & Central America is experiencing growth due to a combination of rising obesity rates, increased health awareness, and expanding access to healthcare services. Sedentary lifestyles and changing dietary habits have contributed to a surge in overweight and obesity prevalence, prompting governments and health organizations to prioritize weight management. Additionally, growing urbanization and economic development have led to greater healthcare infrastructure and increased availability of pharmaceutical products. Public health campaigns and media coverage have also helped reduce the stigma around obesity, encouraging more individuals to seek medical treatment. Moreover, the introduction of innovative and more effective anti-obesity drugs, including GLP-1 receptor agonists, has boosted patient interest and physician confidence. As medical tourism rises in some countries, the region is also becoming a destination for affordable treatments. Collectively, these factors are driving market expansion and attracting investments from major pharmaceutical companies aiming to tap into this growing demand.

South & Central America Anti-Obesity Drugs Market: Strategic Insights

South & Central America Anti-Obesity Drugs Market Segmentation Analysis:

• By Type, the South & Central America Anti-Obesity Drugs Market is segmented into Prescription Drugs and OTC Drugs. Prescription Drugs held the largest share of the market in 2024.
• By Mechanism of Action, the South & Central America Anti-Obesity Drugs Market is segmented into Centrally Acting Drugs, Peripherally Acting Drugs, and Others. Centrally Acting Drugs held the largest share of the market in 2024.
• By Drug Class, the South & Central America Anti-Obesity Drugs Market is segmented into GLP-1 Agonist, Lipase Inhibitors, MC4R agonist, and Others. GLP-1 Agonist held the largest share of the market in 2024.
• By GLP-1 agonist, the South & Central America Anti-Obesity Drugs Market is segmented into Semaglutide, Liraglutide, and Tirzepatide (Zepbound). Semaglutide held the largest share of the market in 2024.
• By Application, the South & Central America Anti-Obesity Drugs Market is segmented into Appetite Suppression, Inhibition of Fat Absorption or Digestive Enzymes, Metabolic Enhancement, and Combination. Appetite Suppression held the largest share of the market in 2024.
• By Route of Administration, the South & Central America Anti-Obesity Drugs Market is segmented into Oral and Parenteral. Oral held the largest share of the market in 2024.
• By Distribution Channel, the South & Central America Anti-Obesity Drugs Market is segmented into Hospital Pharmacies, Online Channel, and Retail Pharmacies. Hospital Pharmacies held the largest share of the market in 2024.

South & Central America Anti-Obesity Drugs Market Players Density: Understanding Its Impact on Business Dynamics

The South & Central America Anti-Obesity Drugs Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

South & Central America Anti-Obesity Drugs Market Outlook

Expansion in emerging economies presents a significant opportunity for the anti-obesity drugs market due to rising obesity rates driven by urbanization and lifestyle changes. Increasing healthcare infrastructure and growing awareness about obesity-related health risks are encouraging demand for effective treatments. Additionally, improving access to healthcare and pharmaceuticals in these regions supports market growth. Pharmaceutical companies are investing in these markets to tap into the unmet need for weight management solutions. As a result, emerging economies are becoming key growth drivers for the global anti-obesity drugs market.

Brazil is enhancing healthcare infrastructure and obesity management programs, fostering a supportive environment for the introduction and reimbursement of new anti-obesity medications. In April 2024, Brazil opened a laboratory in Hortolândia, São Paulo State, dedicated to producing medications for diabetes and obesity, including liraglutide, an active ingredient found in Ozempic. The EMS-operated plant will also produce semaglutide, a key ingredient in Ozempic, which has a patent valid until March 2026 and is already under review by Agência Nacional de Vigilância Sanitária (ANVISA). With an investment of R$60 million (~US$ 10.93 million), this facility is the first of its kind in Brazil and supports the federal government's Health Economic-Industrial Complex initiatives.

According to the World Economic Forum, initial access to anti-obesity medications may be limited to private markets and out-of-pocket payments. Still, future insurance coverage and generic versions in middle-income countries could improve the accessibility of these medications. The rising obesity prevalence in emerging economies, combined with expanding healthcare infrastructure and growing awareness, is driving increased demand for anti-obesity drugs. Pharmaceutical investments and government initiatives are fostering an environment conducive to market growth. Although initial access may be limited by cost, future insurance coverage and generic options are expected to enhance accessibility. These factors collectively position emerging markets as key growth areas for the South & Central America anti-obesity drugs market.

South & Central America Anti-Obesity Drugs Market Country Insights

By country, the South & Central America Anti-Obesity Drugs Market is segmented into Brazil, Argentina, and the Rest of South & Central America. The Rest of South & Central America held the largest share in 2024.

Chile, Colombia, Peru, and Bolivia are major countries in the anti-obesity drugs market in the Rest of South & Central America. According to an article published in March 2025, Chileans are the most obese in South America. Chile stands at the forefront of South America's obesity crisis, with ~42% of adults classified as the highest rate in the region. This prevalence is projected to affect 14 million Chileans within the next five years. Additionally, 83% of Chilean adults are overweight, and 20% of children under 19 suffer from obesity. The surge in obesity is attributed to the widespread availability and affordability of ultra-processed foods, particularly in urban areas. These dietary habits, coupled with limited physical activity, have led to a significant increase in obesity-related health issues, including type 2 diabetes, cardiovascular diseases, and certain cancers.

Colombia's healthcare system underwent significant reforms in the 1990s, expanding coverage and improving access to medical services. By 2023, approximately 97% of the population was covered under the social and health security system. This expanded coverage has facilitated greater access to healthcare services, including obesity treatments, thereby contributing to the market growth.

South & Central America Anti-Obesity Drugs Market Company Profiles

Some of the key players operating in the market include GSK Plc, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Novo Nordisk AS, Eli Lilly and Co, Sun Pharmaceutical Industries Ltd, VIVUS LLC, Currax Pharmaceuticals LLC., AdvaCare Pharma USA LLC, and Rhythm Pharmaceuticals Inc

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

South & Central America Anti-Obesity Drugs Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note:

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise